Amarin, Omeros fall after follow-ons

Shares of Amarin Corp. plc (NASDAQ:AMRN) and Omeros Corp. (NASDAQ:OMER) both slipped on Thursday after the companies priced follow-ons.

Amarin raised $60.1 million through the sale of 21.1 million ADSs at $2.85. Each ADS represents one share. The company proposed the offering after market close on Wednesday, when its share price was $3.32. Amarin lost $0.25 to $3.07 on Thursday. Jefferies, Citigroup, Cantor Fitzgerald, H.C. Wainwright and SunTrust are underwriters. Amarin markets hypertriglyceridemia drug Vascepa icosapent ethyl. The company expects data in 2018 from the Phase III REDUCE-IT cardiovascular outcomes study comparing Vascepa plus a statin vs. placebo plus a statin. ...